A phase I trial of F 573 as a treatment for viral hepatitis.

Trial Profile

A phase I trial of F 573 as a treatment for viral hepatitis.

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2011

At a glance

  • Drugs F 573 (Primary)
  • Indications Viral hepatitis
  • Focus Adverse reactions
  • Sponsors GNI; Shanghai Genomics
  • Most Recent Events

    • 01 Jul 2011 Shanghai Genomics filed an IND application for F 573 in China, according to a EpiCept Corporation media release.
    • 28 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top